Study S001576

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05162183
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 3474
Start: 2019-09-01
Primary completion: 2021-09-01
Lead sponsor: Brigham and Women's Hospital
Conditions: Diabetes
Interventions: DRUG:Glimepiride; DRUG:Liraglutide
Results posted: FALSE

Registered primary outcomes

Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up) [26-week follow-up window with a median follow-up time of 99 [84, 148] days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.